Loading data
MDCXNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research and development expense | 7.72 m USD | 3.53 m USD | 193.58 k USD |
| Operating profit | -34.36 m USD | -11.18 m USD | -4.73 m USD |
| Income tax expense | 0 USD | 0 USD | 0 USD |
| Net income (reported basis) | -47.28 m USD | -11.16 m USD | -5.31 m USD |
| Net income attributable to common shareholders | -47.28 m USD | -11.16 m USD | -5.31 m USD |
| Basic earnings per share | -2.74 USD/share | -1.16 USD/share | -1.53 USD/share |
| Diluted earnings per share | -2.74 USD/share | -1.16 USD/share | -1.53 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.